JAMA Oncology Author Interviews podcast

Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint–Based Therapy in Patients With Advanced NSCLC

0:00
15:06
Spola tillbaka 15 sekunder
Spola framåt 15 sekunder

Fler avsnitt från "JAMA Oncology Author Interviews"